These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21602310)

  • 1. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.
    Schiffman M; Glass AG; Wentzensen N; Rush BB; Castle PE; Scott DR; Buckland J; Sherman ME; Rydzak G; Kirk P; Lorincz AT; Wacholder S; Burk RD
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1398-409. PubMed ID: 21602310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
    Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
    J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
    Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
    Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
    Dillner J; Rebolj M; Birembaut P; Petry KU; Szarewski A; Munk C; de Sanjose S; Naucler P; Lloveras B; Kjaer S; Cuzick J; van Ballegooijen M; Clavel C; Iftner T;
    BMJ; 2008 Oct; 337():a1754. PubMed ID: 18852164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
    Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
    JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
    Castle PE; Solomon D; Schiffman M; Wheeler CM
    J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
    Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
    J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.